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Objective: Cluster headache (CH) is the most severe primary headache condition. Its patho-
physiology is multifaceted and incompletely understood. This review brings together the latest 
neuroimaging and neuropeptide evidence on the pathophysiology of CH.
Methods: A review of the literature was conducted by searching PubMed and Web of Sci-
ence. The search was conducted using the following keywords: imaging studies, voxel-based 
morphometry, diffusion-tensor imaging, diffusion magnetic resonance imaging, tractography, 
connectivity, cerebral networks, neuromodulation, central modulation, deep brain stimula-
tion, orexin-A, orexin-B, tract-based spatial statistics, single-photon emission computer 
tomography studies, positron-emission tomography, functional magnetic resonance imag-
ing, magnetic resonance spectroscopy, trigeminovascular system, neuropeptides, calcitonin 
gene-related peptide, neurokinin A, substance P, nitric oxide synthase, pituitary adenylate 
cyclase-activating peptide, vasoactive intestinal peptide, neuropeptide Y, acetylcholine, 
noradrenaline, and ATP. “Cluster headache” was combined with each keyword for more 
relevant results. All irrelevant and duplicated records were excluded. Search dates were 
from October 1976 to May 2018.
Results: Neuroimaging studies support the role of the hypothalamus in CH, as well as other brain 
areas involved in the pain matrix. Activation of the trigeminovascular system and the release of 
neuropeptides play an important role in CH pathophysiology. Among neuropeptides, calcitonin 
gene-related peptide, vasoactive intestinal peptide, and pituitary adenylate cyclase-activating 
peptide have been reported to be reliable biomarkers for CH attacks, though not specific for 
CH. Several other neuropeptides are involved in trigeminovascular activation, but the current 
evidence does not qualify them as reliable biomarkers in CH.
Conclusion: CH has a complex pathophysiology and the pain mechanism is not completely 
understood. Recent neuroimaging studies have provided insight into the functional and struc-
tural network bases of CH pathophysiology. Although there has been important progress in 
neuropeptide studies, a specific biomarker for CH is yet to be found.
Keywords: voxel-based morphometry, single-photon emission computer tomography, positron-
emission tomography, functional magnetic resonance imaging, calcitonin gene-related peptide, 
pituitary adenylate cyclase-activating peptide
Introduction
Cluster headache (CH) is the most severe primary headache disorder.1 CH has been called 
“suicide headache”, because some patients have taken their lives during an attack or in 
anticipation of an attack.2 According to the International Classification of Headache Dis-
orders, CH is defined as a unilateral condition,1 but bilateral attacks3 or alternating attack 
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sides can occur.4 CH is associated with ipsilateral conjunctival 
injection, lacrimation, nasal congestion, rhinorrhea, forehead 
and facial sweating, miosis, ptosis and/or eyelid edema, and/or 
with restlessness or agitation. A CH attack can last 15 minutes 
to 3 hours, occurring from every other day to eight times a 
day.1 The ways brain function are explored have revolutionized 
the understanding of pain mechanisms in headache disorders. 
Neuroimaging techniques and neuropeptide studies in CH are 
included in this review.
Methods
A review of the literature was carried out by searching 
PubMed and Web of Science. The search was conducted 
using the following keywords: imaging studies, voxel-based 
morphometry, diffusion-tensor imaging, diffusion magnetic 
resonance imaging, tractography, connectivity, cerebral 
networks, neuromodulation, central modulation, deep-brain 
stimulation, orexin-A, orexin-B, tract-based spatial statistics, 
single-photon-emission computed tomography studies, pos-
itron-emission tomography, functional magnetic resonance 
imaging, magnetic resonance spectroscopy, trigeminovascu-
lar system, neuropeptides, calcitonin gene-related peptide, 
neurokinin A, substance P, nitric oxide synthase, pituitary 
adenylate cyclase-activating peptide, vasoactive intestinal 
peptide, neuropeptide Y, acetylcholine, noradrenaline, and 
ATP. “Cluster headache” was combined with each keyword 
for more relevant results (eg, “cluster headache” + “imag-
ing studies”, “cluster headache” + “neuropeptides”). All 
irrelevant and duplicated records were excluded from con-
sideration. Works published from October 1976 to September 
2018 are presented in the current review.
Results
Imaging studies in CH
The first functional imaging studies in CH used single-
photon-emission computed tomography (SPECT).5–7 They 
were followed by positron-emission tomography (PET)8,9 and 
functional magnetic resonance imaging (fMRI) studies.10,11 
Structural imaging studies used voxel-based morphometry 
(VBM), diffusion-tensor imaging (DTI), tract-based spatial 
statistics (TBSS), and diffusion tractography. The findings 
of imaging studies are summarized in Table 1.
Structural studies
VBM
VBM is a structural imaging technique that allows investiga-
tion of focal differences in brain anatomy, and it is mainly 
used to identify gray-matter alterations. Used in a pioneering 
study by May et al,12 VBM inspired many researchers to use 
the technique in the study of pain. It showed the involvement 
of the posterior hypothalamus in the pathophysiology of CH.12 
The study, conducted on 25 patients, detected significant 
structural differences (increase in volume) in gray-matter 
density among patients with CH compared to controls.12 A 
PET study on the same patient cohort showed activation of 
the same brain area.12 These findings led to the conclusion 
that the changes might be permanent and not a reaction to 
pain, showing a clear correlation between the structural and 
functional changes in CH.12 Matharu, who reproduced the 
study, found no alterations in gray or white matter, suggesting 
that the initial finding might have been due to methodologi-
cal limitations.13
A more recent study, carried out by Absinta et al, 
showed alterations in brain structures involved in pain pro-
cessing (reduced gray-matter volume in the right posterior 
cingulate cortex, the head of the right caudate nucleus, right 
thalamus, left inferior parietal lobe, right middle temporal 
gyrus, left insula, right precentral gyrus, right precentral 
gyrus, and bilateral frontal gyrus).14 Using the same imag-
ing technique, reduction in gray matter in frontal areas was 
detected in 49 patients with CH, findings interpreted as 
dysfunction of the descending pain-modulation systems 
in CH.15 The same study detected gray-matter increase in 
the anterior cingulate gyrus, insula, and fusiform gyrus, 
changes that could represent compensation mechanisms or 
neuroplasticity.15 The largest VBM study showed that brain 
alterations (temporal lobe, hippocampus, insular cortex, 
and cerebellum) were related to disease burden and vari-
able in relation to the pain state.16
Although multiple studies have explored the role of 
the posterior hypothalamus in CH, a recent study showed 
enlargement of the anterior hypothalamus in patients with 
both episodic and chronic CH compared with patients with 
migraine.17 Located in the anterior hypothalamus, the supra-
optic nucleus, which is the endogenous biological clock, 
might cause the circadian and circannual periodicity that 
characterizes CH.17
DTI/TBSS/tractography
DTI is an MRI technique used to estimate the axonal 
white-matter organization of the brain. The data are 
collected by diffusion weighted imaging. The main 
parameters measured with DTI are fractional anisotropy 
and diffusivity.18,19 Anisotropy is the property of being 
directionally dependent, which implies different prop-
erties in different directions, as opposed to isotropy.18 
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Table 1 Neuroimaging and biochemical studies
Modality/analysis 
method
Subjects and 
diagnosis
Main findings
Structural studies
May et al12 sMRI-T1W/VBM 25 ECH Increase in bilateral posterior hypothalamic GM
Matharu13 sMRI-T1W/VBM 66 ECH No significant changes in GM and WM
Owen et al28 DW-MRI/probabilistic 
tractography
1 CCH No CH attacks at 8 months after the DBS electrode was placed 6 mm 
posterior to the hypothalamus, 2 mm lateral, and 8 mm below the 
midcommissural point
Absinta et al14 sMRI-T1W/VBM and TBSS 15 ECH 1. GM decrease in the pain network
2. GM increase in the right cuneus
3. No changes seen within the hypothalamus
Teepker et al22 sMRI-DTI/TBSS 7 ECH Widespread WM alterations involved in trigeminal/nociceptive processing
Seifert et al30 sMRI-T1W/whole-brain 
surface-based comparison 
of cortical thickness
12 ECH Cortical thinning in the contralateral angular and precentral gyrus
Yang et al15 sMRI-T1W/VBM 49 ECH 1. GM-volume reduction in frontal areas
2. GM increase in the ACC, fusiform gyrus, and insula (longitudinal analysis)
Szabo et al23 sMRI-DTI/TBSS 13 ECH Widespread reduction in FA and increase in diffusivity (contralateral 
dominance)
Naegel et al118 sMRI-T1W/VBM 68 ECH,  
23 CCH
GM-volume alterations in the temporal lobe, hippocampus, insular cortex, 
and cerebellum
Chou et al20 sMRI-DTI/TBSS 17 ECH High diffusivity in the left frontal gyrus and lower diffusivity in the right 
parahippocampal gyrus
Kiraly et al24 sMRI-T1W and DTI/FSL 22 ECH 1. Increased FA of the right amygdala
2. Increased diffusivity in the right caudate
3. High radial diffusivity and lower anisotropy in the right pallidus
Arkink et al17 sMRI-T1W/VBM 24 ECH
23 CCH
14 Probable 
CH
Increased volume of the anterior hypothalamus in patients with ECH and 
CCH; similar trends, but not significant in patients with probable CH
Akram et al26 DW-MRI/VBM/
probabilistic diffusion 
tractography
7 CCH The DBS-activated area posterior to the hypothalamus in the ventral 
tegmental area lies on the tract that connects the hypothalamus, 
prefrontal, and temporal regions with brain-stem area
Seijo-Fernandez 
et al27
DW-MRI/probabilistic 
diffusion tractography
15 CCH Projections between the DBS target areas and ipsilateral cerebellum and 
reticular nucleus
Functional studies
Norris et al5 SPECT/ROI 1 ECH No changes in mean CBF
Sakai and Meyer6 SPECT/ROI 8 ECH Increased CBF
Henry et al7 SPECT/ROI 3 ECH No changes in mean CBF
Nelson et al31 SPECT/ROI 26 ECH Variable changes in mean CBF (increase or decrease)
Krabbe et al32 SPECT/ROI 9 ECH, 9 CCH No changes in mean CBF
Di Piero et al33 SPECT/ROI 7 ECH Decreased CBF in the posterior parietal cortex and thalamus contralateral 
to the pain side
Hsieh et al8 PET/VBA and ROI 7 ECH 1. Decreased rCBF in the frontal cortex, posterior parietal cortex, and 
occipitotemporal regions
2. Increased rCBF in the ACC, frontal cortex, insula, putamen, and 
temporopolar region with preference of the right hemisphere
May et al9 PET/VBA 9 CCH 1. Exclusive activation during CH attacks of the inferior hypothalamic gray 
matter ipsilateral to the headache side
2. Increased rCBF in the ventroposterior thalamus, ACC, and insula 
bilaterally
May et al12 PET/VBM 17 ECH Activation of inferior posterior hypothalamus ipsilateral to the headache 
side
May et al35 PET and MRA/VBA 17 ECH 1. Activation of inferior posterior hypothalamus, frontal lobes, insula 
bilaterally, ACC bilaterally, ipsilateral thalamus, ipsilateral basal ganglia, and 
contralateral inferior frontal cortex
2. Increased CBF in the ICA ipsilateral to the headache side
(Continued)
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Modality/analysis 
method
Subjects and 
diagnosis
Main findings
Sprenger et al36 PET/VBA and ROI 1 CHH 1. Activation of inferior hypothalamic gray matter
2. Increased rCRB in medial thalamus and contralateral ACC
Sprenger et al37 PET/VBA and ROI 6 ECH
1 CCH
Decreased tracer binding in the pineal gland
Sprenger et al38 PET/VBA 11 ECH 1. Increases in metabolism in the ACC, posterior cingulate cortex, 
prefrontal cortex, insula, thalamus, and temporal cortex
2. Decreases in metabolism in the cerebellopontine area, perigenual ACC, 
and prefrontal and orbitofrontal cortices
Morelli et al10 fMRI/VBA 4 ECH Activation of hypothalamus ipsilaterally to the pain side, prefrontal cortex, 
ACC, contralateral thalamus, ipsilateral basal ganglia, insula bilaterally, and 
cerebellar hemispheres
Rocca et al11 fMRI/ICA and SB-FCA 13 ECH 1. Decreased fluctuations in primary visual and sensorimotor networks
2. Increased FC in the hypothalamus and thalamus
Magis et al45 FDG-PET 10 CCH Metabolic normalization in pain-matrix areas and absent short-term 
changes induced by ONS
Qiu et al41 fMRI/SB-FCA 12 ECH Abnormal FC of the hypothalamus located mainly in the pain system 
during spontaneous CH attacks; extends beyond the pain system during 
CH-attack intervals
Qiu et al42 fMRI/ICA 21 ECH 1. Decreased functional coactivation between the hypothalamus, both 
ipsilateral and contralateral to the headache side
2. SN in patients with right-sided or left-sided CH
Yang et al43 fMRI/SB-FCA 18 ECH 1. Hypothalamic FC changes with the medial frontal gyrus and occipital 
cuneus during and outside CH attacks
2. Annual bout frequency correlated with hypothalamic FC in cerebellar 
areas
Chou et al44 fMRI/ICA 17 ECH 1. FC changes in the temporal, frontal, salience, default mode, 
somatosensory, dorsal attention, and visual networks, independently of 
bout period
2. Altered FC in the frontal and dorsal attention networks during CH 
attacks
Farago et al119 fMRI/ICA 17 ECH Increased connectivity in attention network ipsilateral to the headache 
side and in the contralateral cerebellar network
Ferraro et al120 RS-fMRI 17 CCH 1. Increased functional connectivity between the posterior hypothalamus 
and ventral tegmental area, dorsal raphe nuclei, bilateral substantia nigra, 
subthalamic nucleus, and red nucleus
2. No difference between patients and controls found in the contralateral 
hypothalamic regions
Biochemical studies
Montagna et al47 31P-MRS/ROI 14 CH Reduced phosphocreatine levels, increased ADP concentration, reduced 
phosphorylation potential, and high relative rate of ATP biosynthesis
Lodi et al48 31P-MRS/ROI 13 CH Reduced cytosolic free Mg2+ and free energy released by the reaction of 
ATP hydrolysis
Lodi et al49 1H-MRS/ROI 18 ECH, 8 
CCH
Reduced hypothalamic N-acetylaspartate/creatine
Wang et al50 1H-MRS/ROI 47 ECH Reduced hypothalamic N-acetylaspartate/creatine and choline/creatine
Abbreviations: 31P-MRS, phosphorus magnetic resonance spectroscopy; ACC, anterior cingulate cortex; CCH, chronic cluster headache; DBS, deep-brain stimulation; DTI, 
diffusion-tensor imaging; DW-MRI, diffusion-weighted magnetic resonance imaging; ECH, episodic cluster headache; FA, fractional anisotropy; FC, functional connectivity; 
FDG-PET, fluorodeoxyglucose positron-emission tomography; GM, gray matter; ICA, independent component analysis; ICA, internal carotid artery; 1H-MRS, proton MRS; 
MRA, magnetic resonance angiography; ONS, occipital nerve stimulation; rCRB, regional cerebral blood flow; ROI, region of interest; RS-fMRI, resting-state functional MRI; 
SB-FCA, seed-based functional connectivity analysis; SN, salience network; SPECT, single-photon-emission computed tomography; T1W, T1-weighted; TBSS, tract-based 
spatial statistics; VBA, voxel-based analysis; VBM, voxel-based morphometry; WM, white matter; rCBF, regional cerebral blood flow; sMRI, structural MRI.
Table 1 (Continued)
Fractional anisotropy is a scalar value from zero to one 
and describes the anisotropy of a diffusion process. 
Fractional anisotropy with a value of zero means the 
diffusion is isotropic (unrestricted or equally restricted 
in all directions). A value of one means that the diffusion 
affects one axis and is restricted along the other axis.19,20 
Statistical analysis is performed using TBSS.21 TBSS 
uses nonlinear image transformation that combines 
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the strength of both voxelwise and tractography-based 
analyses.21
The VBM study performed by Absinta et al used a DTI/
TBSS analysis on the same sample of patients, but no sig-
nificant change in fractional anisotropy or diffusivity was 
found.14 Another three studies that used DTI to explore brain 
changes in CH found widespread alterations in the pain-
processing system (“pain matrix”).20,22,23 Interictal alterations 
in subcortical structures are present in CH (right amygdala, 
right caudate, right pallidus).24 Some of the microstructural 
changes are related to lifetime disease burden, suggesting 
that recurring painful episodes might trigger maladaptive 
plasticity or degenerative processes.24
Diffusion tractography is used to identify brain connec-
tivity along white-matter pathways.25 Tractography studies 
have shown that the deep brain stimulation (DBS)-activated 
area lies in the ventral tegmental area, posterior to the hypo-
thalamus,26–28 and projects to the ipsilateral cerebellum and 
reticular nucleus.28,29
Other structural imaging studies
Seifert et al conducted a high-resolution T
1
-weighted MRI 
study and performed whole-brain surface-based comparison 
of cortical thickness.30 The study showed cortical thickening 
in patients with CH, implying involvement of the cortical 
structures in the pathogenesis of CH.30
Functional studies
SPECT
SPECT was used as an early neuroimaging technique to 
evaluate cerebral blood flow by 133Xe inhalation. Studies 
have shown varied results: some reported increases,6,31 others 
decreases,31 and some no changes5,7,32 in cerebral blood flow. 
The last SPECT study showed reduced cerebral blood flow in 
the thalamus and posterior parietal areas contralateral to the 
pain side, hypothesizing early on the involvement of these 
brain areas in CH pathophysiology.33
PET
PET is a nuclear medicine magnetic imaging technique that 
detects γ-rays emitted by a positron-emitting radionuclide 
(tracer). The biological molecule chosen for PET is flude-
oxyglucose, an analog of glucose.34 Hsieh et al conducted 
the first nitroglycerin-induced PET study on seven patients 
with episodic CH in 1996, and showed activation of brain 
areas involved in central nociception with preference for 
the right hemisphere.8 Although the initial PET study did 
not show activation of the hypothalamus, a study conducted 
by May et al 2 years later showed activation of the inferior 
hypothalamic gray matter ipsilateral to the headache side 
during nitroglycerine-induced attacks.9 A later PET/mag-
netic resonance angiography study by the same group on a 
larger population of 17 patients with episodic CH showed 
activation of the inferior posterior hypothalamus and brain 
areas involved in pain processing.35 Significant dynamic 
changes in brain metabolism during and outside CH attacks 
were detected by three PET studies carried out by Sprenger 
et al.36–38
fMRI
fMRI measures brain activity by detecting changes associated 
with blood flow, and relies on the fact that blood flow and 
cerebral activation are coupled. When a brain area is active, 
the blood flow to that area increases.39 The primary form 
of fMRI uses blood-oxygen-level-dependent contrast and 
measures changes in blood flow and tissue oxygenation.39 
Resting-state fMRI is a technique that assesses baseline brain 
activity when subjects are not performing any task, in contrast 
to task-specific fMRI.40 In the first fMRI study, Morelli et al 
showed activation of the hypothalamus during CH attacks and 
activation of other brain areas involved in pain processing.10 
The role of the hypothalamus in the pathophysiology of CH 
was strengthened by several studies that found abnormal 
functional connectivity of the hypothalamus.11,41–44 Involve-
ment of the pain matrix and nontraditional pain-processing 
areas (eg, salience networks, occipital area, cerebellar net-
work) were also found.40,44 Metabolic normalization in the 
pain-matrix areas and absent short-term changes induced 
by occipital nerve stimulation (ONS) might support the 
hypothesis that ONS, a symptomatic treatment for CH, works 
through slow neuromodulation.45
Biochemical studies
31P magnetic resonance spectroscopy (MRS) can be used as 
a noninvasive tool for measuring relative intracellular con-
centrations of phosphorus containing metabolites in different 
organs.46 Montagna et al conducted the first 31P-MRS study 
on 14 patients with CH and showed abnormalities in brain-
energy metabolism, with reduced phosphocreatine levels, 
increased ADP, reduced phosphorylation potential, and high 
relative rate of ATP biosynthesis.47 A few years later, Lodi 
et al showed reduced cytosolic free Mg2+ and free energy 
released by the reaction of ATP hydrolysis.48 The first in vivo 
proton MRS (1H-MRS) studies to show the involvement of 
the hypothalamus in CH pathophysiology were performed in 
2006.49,50 1H-MRS allows noninvasive measurement of signal 
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intensities derived from N-acetylaspartate, creatine, and phos-
phocreatine and choline-containing compounds.51 The studies 
showed reduced hypothalamic N-acetylaspartate:creatine49,50 
and choline:creatine ratios48 in patients with CH.
Trigeminovascular pain pathways and 
neuropeptides
Anatomy of the trigeminovascular pain pathways
The trigeminovascular system includes the trigeminal ganglion, 
the meningeal vasculature, and distinct nuclei of the brain stem, 
thalamus, and the somatosensory cortex (Figure 1).52 Pseu-
dounipolar primary afferent fibers from the trigeminal ganglion 
synapse on intra- and extracranial structures.52 Nociceptive 
fibers innervating the pial, arachnoid, and dural blood ves-
sels, including large cerebral arteries, superior sagittal sinus, 
and middle meningeal artery, arise from the trigeminal nerve, 
mostly V1.53 On the other hand, sensory fibers innervating the 
posterior fossa and basilar arteries are located in the C1–C3 
dorsal root ganglia.54 Projections from the trigeminal ganglion 
and upper cervical nerve roots converge at the trigeminocervi-
cal complex. Second-order neurons from the trigeminocervical 
complex ascend in the trigeminothalamic tract and synapse 
with third-order neurons.53 The third-order thalamocortical 
neurons synapse with a complex cortical network including 
the primary and secondary motor, sensory, and visual areas.53 
There are direct and indirect ascending projections to the 
hypothalamus, periaqueductal gray, and locus coeruleus.55 
There is a reflex connection from the trigeminal nucleus to the 
superior salivatory nucleus, which projects via sphenopalatine 
ganglion.53 Additional ascending projections exist to the insula, 
retrosplenial cortex, ectorhinal areas, rostral ventromedial 
medulla, parietal associations, and auditory areas.53
The thalamus is the relay center involved in the modula-
tion and processing of all incoming sensory information.56 
The pain matrix, which includes the thalamus, primary and 
secondary somatosensory areas, anterior cingulate gyrus, and 
prefrontal cortex, is active during nociceptive processing.56 
Furthermore, indirect projections from the trigeminal nucleus 
to the amygdala and hippocampus are likely to be involved in 
the processing of cognitive and affective responses to pain.57
Activation of the trigeminovascular system
In vivo human studies have shown activation of the trigemino-
vascular system during acute CH attacks,58 with distribution 
of pain in the ophthalmic division of the trigeminal nerve.1 
Parasympathetic activation as a component of CH attacks 
Figure 1 Ascending pathways of the trigeminovascular system.
Notes: Reproduced from Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. 
Physiol Rev. 2017;97(2):553–622.53
Abbreviations: TCC, trigeminocervical complex; SusS, superior salivatory nucleus; LC, locus coeruleus; Ins, insula; RS, retrosplenial; Ect, ectorhinal; RVM, rostral 
ventromedial medulla; PtA, parietal association area; Au, auditory association area; TG, trigeminal ganglion; SPG, sphenopalatine ganglion; PAG, periaqueductal grey; M1/M2, 
primary and secondary motor area, S1/S2, primary and secondary sensory areas; V1/V2, primary and secondary visual areas.
Thalamus
Hypothalamus
SPG
SUS
RVM
TCC
LC
PAG
RS
Ect
V1/V2
Au
PtA
S2
S1
Ins
M1/M2
TG
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involves the activation of the trigeminal-autonomic reflex,59 
and manifests clinically as lacrimation, nasal congestion, 
and rhinorrhea. Activation of the parasympathetic fibers is 
mediated through the facial nerve.60 Sphenopalatine ganglion 
stimulation is known to relieve CH pain.61 The sympathetic 
overactivity could be explained by dilatation of the carotid 
artery secondary to parasympathetic activation and subse-
quent compression on the periarterial plexus of sympathetic 
fibers.62 However, parasympathetic overactivity alone could 
be responsible for the ocular sympathetic deficit.62
Neuropeptides involved in trigeminovascular system 
activation
Activation of the trigeminovascular system leads to neuropep-
tide release. Nerve fibers are classified based on their neuro-
peptide content. Trigeminal sensory fibers contain calcitonin 
gene-related peptide (CGRP), neurokinin A, substance P, nitric 
oxide synthase, and pituitary adenylate cyclase-activating pep-
tide (PACAP), parasympathetic nerve fibers are rich in vaso-
active intestinal peptide (VIP), neuropeptide Y, acetylcholine, 
nitric oxide synthase, and PACAP, and sympathetic nerve fibers 
contain norepinephrine, ATP, and neuropeptide Y (Table 2).52,53
Trigeminal sensory nerve fibers
CGRP
CGRP is the most potent vasodilator and expressed mainly in 
the central nervous system.63 It contains 37 amino acids and 
has two isoforms: αCGRP (CGRP1), located in the central 
and peripheral nervous systems, and βCGRP (CGRP2), 
Table 2 Craniovascular nerve fibers and their vasoactive neuropeptides
Neuropeptide/neurotransmitter Role of neuropeptide/neurotransmitter
Trigeminal sensory 
nerve fibers
Calcitonin gene-related peptide Vasodilatation and plasma extravasation63
Neurokinin Initiation of expression of cytokines74
Substance P Vasodilatation68 and plasma extravasation69
Initiation of expression of cytokines
Nitric oxide synthase Regulates blood flow (vasodilatation)86
Prevents platelet activation86
Inhibits monocyte adhesion and leukocyte function86
Pituitary adenylate cyclase-activating peptide (PACAP) Vasodilatation77
Parasympathetic  
nerve fibers
Vasoactive intestinal peptide Potent vasodilator89
Proinflammatory and anti-inflammatory effects89
Neuropeptide Y Vasodilatation94
Acetylcholine Vasodilatation96
Mast-cell degranulation96
Nitric oxide synthase Vasodilatation86
PACAP Vasodilatation77
Sympathetic nerve 
fibers
Norepinephrine Potent vasoconstrictor101
ATP Vasoconstriction100
Neuropeptide Y Vasoconstriction94
Notes: Reproduced from Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. 
Physiol Rev. 2017;97(2):553–622.53
distributed in the enteric nerve fibers.64 Although the role of 
CGRP has been studied extensively in migraine, several stud-
ies have shown the implication of CGRP in CH pathophysiol-
ogy.58,65,66 Patients with spontaneous or nitroglycerine-induced 
CH attacks were found to have increased CGRP levels in the 
external jugular vein that was normalized after O
2
 inhalation 
or treatment with subcutaneous sumatriptan 6 mg.58,65,66 Phase 
III clinical trials with CGRP monoclonal antibodies are in 
progress for the preventive treatment of episodic and chronic 
CH (NCT03107052, NCT02797951).
Substance P
Substance P is the first responder to most noxious stimuli, 
and is an immediate defense, stress, repair, and survival 
system.67 Its receptor, neurokinin type 1, is distributed in 
many tissue types and organs.67 Substance P is responsible 
for multiple functions. It is a potent vasodilator,68 has a role 
in inflammation initiating the expression of cytokines,69 
and is involved in nociception and the regulation of mood 
disorders.70 Substance P activity can be measured indirectly 
by assessing opiate and somatostatin activity, both active in 
relieving CH attacks, which inhibit substance P.71 Changes 
in substance P immunoreactivity have been shown during 
spontaneous and histamine-induced CH attacks, suggesting a 
possible involvement of substance P in CH pathophysiology.71 
Trigeminovascular system activation in cats induces release 
of substance P in the extracerebral circulation.72 Decreased 
substance P after administration of hyperbaric O
2
 has been 
found in patients with CH compared to controls.73
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
0.
5.
14
8.
19
8 
on
 1
9-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research 2019:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
276
Buture et al
Neurokinin A
Neurokinin A (formally known as substance K) has an impor-
tant contribution to nociceptive processing and inflammatory 
response, initiating the release of cytokines.74 Neurokinin 
A, together with CGRP and substance P, is released from 
the caudal trigeminal nucleus of the rat during electrical 
stimulation of the trigeminal ganglion.75 The main role of 
neurokinin A is vasodilatation. The order of potency is CGRP 
> substance P > neurokinin A.58
PACAP
PACAP is involved in the regulation of important biological 
functions and is located in the brain and peripheral organs, 
notably the endocrine pancreas, gonads, and respiratory and 
urogenital tracts.76 PACAP is found in both trigeminal sensory 
and parasympathetic fibers, and its main role is vasodilata-
tion.77 Although the role of PACAP has been more exten-
sively studied in migraine,78–80 it was shown that PACAP38 
is released during CH attacks, with significantly low levels 
during the interbout period.81
Nitric oxide synthase
Nitric oxide synthases are a family of enzymes catalyzing the 
production of nitric oxide from l-arginin.82 Nitric oxide is a 
signaling molecule found in most tissue in the body. Among 
many other roles, nitric oxide controls neurotransmission 
and vascular tone.82 Nitric oxide production is correlated 
with disease activity of inflammatory disorders, such as 
multiple sclerosis,83 systemic lupus erythematosus,84 and 
bacterial meningitis.85 Nitric oxide synthase regulates blood 
flow (vasodilatation), prevents platelet activation, and inhibits 
monocyte adhesion and leukocyte function.86 Nitrates, which 
are reduced to nitric oxide in the body, are well-known head-
ache triggers.82 Enhanced nitric levels have been found in the 
plasma87 and cerebrospinal fluid82 of patients with CH during 
active and remission periods. It has been shown that genetic 
variations within the nitric oxide synthase gene are less likely 
to contribute to CH susceptibility.88
Parasympathetic nerve fibers
VIP
VIP is a peptide hormone of 28 amino-acid residues that 
belongs to a glucagon/secretin family. VIP is a potent vaso-
dilator, and has proinflammatory and anti-inflammatory 
effects.89 VIP is found in the parasympathetic nervous system 
and supraoptic nucleus, as well as the digestive and cardio-
vascular systems.90 Elevated VIP plasma levels have been 
found during CH attacks and migraine, suggestive of intense 
 parasympathetic activation.72 Serum VIP, but not CGRP, lev-
els seem to reflect the rate of activation of the parasympathetic 
arm of the trigeminovascular system in migraines,91 but there 
are no studies that have tested the same in patients with CH.
Neuropeptide Y
Neuropeptide Y is a 36 amino-acid neuropeptide and the 
most abundant peptide in the central and peripheral nervous 
systems. Neuropeptide Y is found in a high number of neu-
rons of parasympathetic ganglia, but is produced mainly by 
the sympathetic nervous system. In the human brain, neuro-
peptide Y expression is highly concentrated in hypothalamic 
nuclei, basal ganglia, and the limbic system.92 Neuropeptide 
Y can modulate nociceptive trigeminovascular transmission 
in second-order neurons after peripheral systemic administra-
tion.93 Its main role is vasoconstriction, although it can also 
have a vasorelaxant effect.94 Early experiments did not find 
changes in neuropeptide Y levels in the external jugular vein 
during CH attacks.72 This may suggest that a more localized 
locus of release, eg, the hypothalamic nuclei, would not detect 
neuropeptide Y in the extracranial vessels.
Acetylcholine
Acetylcholine is the neurotransmitter used at the neuromus-
cular junction, and is released by motor neurons to activate 
muscles. Acetylcholine is also used as a neurotransmitter in the 
autonomic nervous system, both as the final product released 
by the parasympathetic nervous system and as an internal 
transmitter for the sympathetic nervous system.95 Parasym-
pathetic fibers originating from the sphenopalatine ganglion 
and trigeminal nerves release acetylcholine, VIP, and PACAP, 
provoking mast-cell degranulation and additional release of 
neurotransmitters, or they can directly affect trigeminal nerves 
inducing nociception.96 It is well known that parasympathetic 
activation is present in CH and other primary headaches. Acute 
electrical stimulation of the sphenopalatine ganglion provides 
significant pain relief and significant and clinically meaningful 
reduction in CH-attack frequency in some patients.61
Sympathetic nerve fibers
Norepinephrine
Norepinephrine, also called noradrenaline, also produced by 
locus coeruleus in the pons, is used as a neurotransmitter by 
the sympathetic ganglia and released into the bloodstream by 
the adrenal glands. Norepinephrine is a potent vasoconstric-
tor. Tyrosine,97 tryptamine,98 and tyramine98 metabolism, all 
involved in norepinephrine production, have been found to be 
abnormal in patients with chronic CH. A primary autonomic 
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dysfunction in CH is also suggested by increased β-receptor 
response to norepinephrine, as shown by Meyer et al.99
ATP
ATP is a complex chemical compound involved in intracel-
lular energy transfer. ATP has several roles as an excitatory 
cotransmitter in the peripheral nerves.100 It is stored with 
noradrenaline in the synaptic vesicles in postganglionic 
sympathetic fibers and has vasoconstriction properties.100 
Existing magnetic spectroscopy studies have shown abnormal 
energy metabolism in patients with CH.47,48
Orexin A and orexin B
Hypocretin, also known as orexin, is produced in the lateral 
and posterior hypothalamus. The hypocretin neuropeptide-
precursor gene encodes a neuropeptide-precursor protein that 
gives rise to orexin A and orexin B, and is involved in a wide 
range of physiological processes, including pain transmission 
and neuroendocrine and autonomic function.102 HCRTR1 
and HCRT2 are hypocretin receptors. A meta-analysis that 
included 593 patients with CH and 599 controls from three 
European studies showed that the 1,246G-A polymorphism 
(rs2653349) in the HCRTR2 gene may modulate the risk 
of CH.103–106 In contrast, the largest population-based study, 
conducted by Weller et al in 2015 on 575 patients with 
CH and 874 controls, found no evidence for association of 
rs2653349 and CH, but a positive association was found in 
the meta-analysis conducted by the same authors on six previ-
ously published studies.107 The meta-analysis results should 
be interpreted with caution, as individual population studies 
have limited power and thus limited validity.107 A study on 
Chinese patients conducted by Fan et al (112 patients with 
CH and 192 controls) did not find a significant association 
between hypocretin-gene polymorphism and CH.108 Given 
the inconsistency of the results from reported studies, the 
exact role of the HCRTR2 gene in CH is yet to be established.
Discussion
Structural and functional imaging studies have revolutionized 
our understanding of the pathophysiology of CH. Several 
neuroimaging studies have identified differences between 
patients with CH and control subjects with respect to brain 
structure. Neuroimaging studies have shown a clear correla-
tion between the structural and functional changes in CH. The 
hypothalamus, an important component of the central nervous 
system that plays a role in homeostasis, autonomic, endocrine 
function, and nociception,109 has been hypothesized to play an 
essential role in initiating CH attacks. Neuroimaging findings 
have determined the use of stereotactic stimulation of the 
activated brain areas identified by structural and functional 
imaging. Although previous reports referred to the posterior 
hypothalamus as the optimal target, tractography studies have 
shown that the DBS-activated area is not located within the 
anatomically defined limits of the hypothalamus.26,110,111 The 
precise anatomical location for DBS refers to the midbrain 
tegmentum, rather than the posterior hypothalamus.29,111 The 
neurons in the ventral tegmental area project to multiple brain 
regions, and are involved in pain modulation, cognition, 
motivation, and behavioral disorders.112
Neuroimaging studies also implicate other brain areas 
generally associated with the pain matrix, such as various 
brain-stem areas, diencephalic structures, prefrontal cortex, 
basal ganglia, and parts of the limbic system.109 The pain 
matrix integrates all the sensory, affective, and cognitive 
responses to pain and becomes active during nociceptive 
processing.53 These areas are involved in a broad range of 
chronic painful diseases and are not specific for headache 
disorders.113 Abnormal metabolism in the perigenual anterior 
cingulate cortex suggests involvement in the descending 
antinociceptive processing in patients with episodic CH.38 
It is recognized that alterations in the central and descend-
ing opioid system contribute to the chronification of pain.114 
The microstructural changes present in patients with CH are 
related to lifetime disease burden, suggesting that recurring 
painful episodes might trigger maladaptive responses.24
The release of neuropeptides as a consequence of tri-
geminovascular system activation has been proposed as a pain 
mechanism in CH and other primary headaches.115 The release 
of these peptides leads to a series of tissue responses, includ-
ing arteriolar vasodilatation, plasma protein extravasation, and 
degranulation of mast cells in their peripheral target tissue.116 
Among sensory neuropeptides, peripheral CGRP levels,58,65,66 
VIP,91 and PACAP3881 are reported to be good biomarkers of 
acute CH attacks. Serum VIP, but not CGRP, levels seem to 
reflect the rate of activation of the parasympathetic arm of 
the trigeminovascular system in migraine,91 but there are no 
studies that have tested the same in patients with CH. Several 
other neuropeptides are involved in trigeminovascular system 
activation (substance P, neurokinin A, nitric oxide synthase, 
neuropeptide Y, acetylcholine, norepinephrine, ATP), but the 
existing evidence does not qualify them as reliable biomarkers 
in CH. Although there is a real need for biomarkers in CH, the 
current data must be interpreted with caution. The elevated 
levels of neuropeptides during CH attacks could only suggest 
activation of the trigeminovascular system, present in other 
primary headaches and not specific for CH.
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Different sites, such as the ventral tegmental area, occipi-
tal nerve, sphenopalatine nerve, and vagus nerve have been 
recognized as relevant pain pathways in the pathophysiology 
of CH. Neurostimulation of these pain pathways can influ-
ence central neurotransmitters.117 Invasive neurostimulation 
techniques are reserved for patients with refractory CH.
Conclusion
Neuroimaging studies have reported three major findings: 
activation of the posterior hypothalamic area during CH 
attacks, involvement of the pain matrix, and involvement of 
the central opioid system. It is debatable whether the activa-
tion seen in these studies is of the midbrain tegmentum or 
the posterior hypothalamus. Among neuropeptides, CGRP, 
VIP, and PACAP38 are reported to be good markers of CH 
attacks, but they are not specific for CH and can only suggest 
activation of the trigeminovascular system. Neurostimula-
tion therapies for refractory CH, such as DBS, ONS, and 
sphenopalatine ganglion stimulation, are important tools in 
understanding CH pathophysiology.
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